Public Employees Retirement System of Ohio Has $2.95 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Public Employees Retirement System of Ohio cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 32.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 113,752 shares of the biotechnology company's stock after selling 54,561 shares during the quarter. Public Employees Retirement System of Ohio's holdings in Exelixis were worth $2,952,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Farallon Capital Management LLC increased its position in shares of Exelixis by 1.6% during the second quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company's stock valued at $608,993,000 after purchasing an additional 424,000 shares during the period. Renaissance Technologies LLC grew its position in Exelixis by 0.4% in the second quarter. Renaissance Technologies LLC now owns 15,163,066 shares of the biotechnology company's stock valued at $340,714,000 after acquiring an additional 61,350 shares during the period. LSV Asset Management grew its position in Exelixis by 107.7% in the second quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company's stock valued at $129,511,000 after acquiring an additional 2,989,021 shares during the period. Dimensional Fund Advisors LP grew its position in Exelixis by 7.3% in the second quarter. Dimensional Fund Advisors LP now owns 5,137,201 shares of the biotechnology company's stock valued at $115,434,000 after acquiring an additional 349,837 shares during the period. Finally, AQR Capital Management LLC grew its position in Exelixis by 12.7% in the second quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company's stock valued at $73,425,000 after acquiring an additional 370,199 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have weighed in on EXEL. BMO Capital Markets upped their price target on Exelixis from $29.00 to $36.00 and gave the company an "outperform" rating in a research report on Wednesday, October 30th. TD Cowen upped their price target on Exelixis from $27.00 to $34.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Guggenheim upped their price target on Exelixis from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Stephens upped their price target on Exelixis from $23.00 to $29.00 and gave the company an "equal weight" rating in a research report on Wednesday, October 30th. Finally, HC Wainwright reiterated a "buy" rating and issued a $29.00 price target on shares of Exelixis in a research report on Wednesday, September 18th. One analyst has rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $31.88.

Exelixis Stock Performance

NASDAQ:EXEL traded down $1.38 during mid-day trading on Tuesday, hitting $34.69. The company had a trading volume of 2,235,182 shares, compared to its average volume of 2,054,013. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $36.97. The business's fifty day moving average is $33.04 and its two-hundred day moving average is $27.38. The firm has a market cap of $9.91 billion, a P/E ratio of 22.24, a P/E/G ratio of 0.89 and a beta of 0.52.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm had revenue of $539.50 million for the quarter, compared to analyst estimates of $490.31 million. During the same quarter in the prior year, the firm posted $0.10 earnings per share. The company's quarterly revenue was up 14.3% on a year-over-year basis. Equities analysts forecast that Exelixis, Inc. will post 1.69 earnings per share for the current year.

Insider Buying and Selling at Exelixis

In related news, Director George Poste sold 30,000 shares of the stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $34.00, for a total transaction of $1,020,000.00. Following the completion of the transaction, the director now directly owns 169,020 shares in the company, valued at approximately $5,746,680. This trade represents a 15.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the transaction, the executive vice president now owns 486,059 shares of the company's stock, valued at approximately $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 339,736 shares of company stock valued at $11,508,610. 2.85% of the stock is currently owned by company insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.